X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (497) 497
Newsletter (42) 42
Newspaper Article (17) 17
Magazine Article (11) 11
Publication (11) 11
Book Review (6) 6
Trade Publication Article (4) 4
Transcript (4) 4
Book Chapter (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
mirabegron (554) 554
overactive bladder (270) 270
index medicus (210) 210
urinary incontinence (166) 166
urology & nephrology (153) 153
humans (148) 148
efficacy (147) 147
urinary bladder, overactive - drug therapy (113) 113
female (101) 101
beta-adrenoceptor agonist (97) 97
male (91) 91
safety (91) 91
double-blind (82) 82
acetanilides - therapeutic use (80) 80
thiazoles - therapeutic use (80) 80
care and treatment (75) 75
aged (72) 72
pharmacology & pharmacy (71) 71
middle aged (69) 69
bladder (60) 60
solifenacin (59) 59
drug therapy (58) 58
research (56) 56
adrenergic beta-3 receptor agonists - therapeutic use (55) 55
treatment outcome (55) 55
tolerability (54) 54
acetanilides - adverse effects (53) 53
thiazoles - adverse effects (53) 53
analysis (50) 50
urology (46) 46
quality-of-life (43) 43
adult (42) 42
antimuscarinics (41) 41
incontinence (41) 41
muscarinic antagonists - therapeutic use (39) 39
urinary-tract symptoms (39) 39
acetanilides - administration & dosage (38) 38
thiazoles - administration & dosage (38) 38
adrenergic beta-3 receptor agonists - adverse effects (37) 37
persistence (37) 37
urinary bladder (37) 37
quality of life (36) 36
urological agents - therapeutic use (36) 36
medicine & public health (35) 35
animals (34) 34
patients (34) 34
symptoms (33) 33
women (32) 32
acetanilides - pharmacology (30) 30
therapy (30) 30
thiazoles - pharmacology (30) 30
urinary-incontinence (29) 29
detrusor overactivity (28) 28
dosage and administration (28) 28
urinary bladder, overactive - physiopathology (28) 28
medical research (27) 27
reports (27) 27
adrenergic beta-3 receptor agonists - pharmacology (26) 26
medicine, experimental (26) 26
urinary bladder - drug effects (26) 26
selective beta-adrenoceptor agonist (25) 25
urological agents - adverse effects (25) 25
adherence (24) 24
aged, 80 and over (24) 24
beta-adrenoceptor (24) 24
dose-response relationship, drug (23) 23
health aspects (23) 23
management (23) 23
obstetrics & gynecology (23) 23
phase-3 (23) 23
tolterodine (23) 23
urodynamics (23) 23
validation (23) 23
adrenergic beta-3 receptor agonists - administration & dosage (22) 22
double-blind method (22) 22
prospective studies (22) 22
antimuscarinic (21) 21
detrusor (21) 21
pharmaceutical industry (20) 20
urological agents - administration & dosage (20) 20
combination therapy (19) 19
diseases of the genitourinary system. urology (19) 19
physical fitness (19) 19
rats (19) 19
urinary-bladder (19) 19
usage (19) 19
benign prostatic hyperplasia (18) 18
clinical trials (18) 18
pharmacokinetics (18) 18
pharmacology/toxicology (18) 18
acetanilides - pharmacokinetics (17) 17
adrenergic receptors (17) 17
beta-adrenoceptor agonist mirabegron (17) 17
expression (17) 17
phase-iii (17) 17
review (17) 17
thiazoles - pharmacokinetics (17) 17
urinary bladder, overactive - diagnosis (17) 17
urination - drug effects (17) 17
drug therapy, combination (16) 16
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (540) 540
French (9) 9
German (8) 8
Spanish (8) 8
Czech (3) 3
Polish (2) 2
Russian (2) 2
Japanese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Pharmacology, ISSN 0007-1188, 07/2019, Volume 176, Issue 14, p. 2525
Linked Articles 
Mirabegron
Journal Article
Der Urologe A, ISSN 0340-2592, 04/2019, Volume 58, Issue 4, p. 432
Journal Article
European Urology, ISSN 0302-2838, 2012, Volume 63, Issue 2, pp. 296 - 305
Abstract Background Despite several antimuscarinic treatment options for overactive bladder (OAB), there is still a need for distinct treatment approaches to... 
Urology | Tolterodine | Overactive bladder | Mirabegron
Journal Article
CELL METABOLISM, ISSN 1550-4131, 01/2015, Volume 21, Issue 1, pp. 33 - 38
Increasing energy expenditure through activation of endogenous brown adipose tissue (BAT) is a potential approach to treat obesity and diabetes. The class of... 
SELECTIVE BETA-ADRENOCEPTOR AGONIST | THERMOGENESIS | ADRENOCEPTOR AGONIST | ENERGY-EXPENDITURE | COLD-EXPOSURE | METABOLISM | MIRABEGRON | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | FAT | ADULT HUMANS | CELL BIOLOGY
Journal Article
Progres en Urologie - FMC, ISSN 1761-676X, 09/2016, Volume 26, Issue 3, pp. F61 - F62
Overactive bladder (OAB) is defined by ICS (International Continence Society) as urgency, with or without urge incontinence, usually with frequency and... 
Anticholinergic | Overactive bladder | Mirabegron
Journal Article
Ceská gynekologie / Ceská lékarská spolecnost J. Ev. Purkyne, ISSN 1210-7832, 08/2015, Volume 80, Issue 4, pp. 244 - 248
Journal Article
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, ISSN 1931-857X, 10/2017, Volume 313, Issue 4, pp. F859 - F861
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 06/2018, Volume 829, pp. 79 - 84
Mirabegron is a β -adrenoceptor agonist and released on the marked for the treatment of overactive bladder. Because mirabegron is the only β -adrenoceptor... 
Cyclic AMP | Platelet aggregation | β3-adrenoceptor | Mirabegron
Journal Article
Journal Article
Journal of Urology, The, ISSN 0022-5347, 2017, Volume 197, Issue 4, pp. 1158 - 1163
Purpose Mirabegron (β3 adrenoreceptor agonist) is a new molecule with a mechanism of action distinct from antimuscarinics. Combination therapy with solifenacin... 
Urology | cholinergic antagonists | mirabegron | overactive | urinary bladder | BETA-ADRENOCEPTOR AGONIST MIRABEGRON | EFFICACY | SAFETY | DETRUSOR OVERACTIVITY | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | SOLIFENACIN | Urinary incontinence | Care and treatment
Journal Article
Therapeutic Advances in Neurological Disorders, ISSN 1756-2864, 01/2019, Volume 12, p. 175628641984345
Background: We investigated the effectiveness and safety of mirabegron oral treatment in a group of patients with Parkinson’s disease (PD) and overactive... 
Journal Article
Neurourology and Urodynamics, ISSN 0733-2467, 08/2019, Volume 38, Issue 6, pp. 1792 - 1792
Journal Article
JOURNAL OF UROLOGY, ISSN 0022-5347, 10/2013, Volume 190, Issue 4, pp. 1320 - 1327
Purpose: Bladder outlet obstruction often presents as storage and voiding symptoms. We investigated urodynamic parameters in men with lower urinary tract... 
OVERACTIVE BLADDER | urinary bladder | TOLERABILITY | TOLTERODINE | MEN | UROLOGY & NEPHROLOGY | urinary bladder neck obstruction | urodynamics | mirabegron | lower urinary tract symptoms
Journal Article
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, ISSN 1756-2856, 05/2019, Volume 12, p. 1756286419843458
Background: We investigated the effectiveness and safety of mirabegron oral treatment in a group of patients with Parkinson's disease (PD) and overactive... 
Parkinson's disease | MANAGEMENT | EFFICACY | SAFETY | mirabegron | DYSFUNCTION | PREVALENCE | overactive bladder | CLINICAL NEUROLOGY | AGONIST
Journal Article
NATURE REVIEWS UROLOGY, ISSN 1759-4812, 06/2017, Volume 14, Issue 6, pp. 330 - 331
Data from an immunohistochemical study reveal abundant expression of beta(3)-adrenoceptors on cholinergic nerves of the human urinary bladder. This finding... 
URINARY-BLADDER | MIRABEGRON | UROLOGY & NEPHROLOGY | CONTRACTIONS
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 07/2015, Volume 758, pp. 115 - 122
Bladder overactivity (OAB) is a multifactorial bladder disorder that requires therapeutics superior to the current pharmacological treatment with muscarinic... 
β 3 -Adrenoreceptors | Pre-junctional receptors | Human detrusor | Overactive bladder | Acetylcholine release | Mirabegron
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.